NCT05090566 2026-02-23MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaPfizerPhase 2 Active not recruiting46 enrolled 15 charts